Please assess the completion status of the following clinical trial:

Trial Title: IntErnational Long-term Follow-up Study of Patients With Uncontrolled HyperTensioN

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subject is ≥ 18 years of age at time of consent~* Subject must be able and willing to provide written informed consent~* Subject must be able and willing to comply with the required follow-up schedule~* Subject has office Systolic Blood Pressure ≥ 140 mmHg at confirmatory visit~* Subject has a daytime mean Systolic Ambulatory Blood Pressure \> 135 mmHg within 90 days prior to procedure~* Subject has established hypertension (diagnosed ≥12 month prior to baseline) and is on a guideline based drug regimen at a stable and fully tolerated dose consisting of ≥ 3 anti-hypertensive medications (including 1 diuretic) or subject has a documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.~Exclusion Criteria:~* Subject has significant renovascular abnormalities such as renal artery stenosis \> 30%~* Subject has undergone prior renal angioplasty, renal denervation, indwelling renal stents, and/or abdominal aortic stent grafts~* Subject has hemodynamically significant valvular heart disease as determined by study investigator~* Subject has a life expectancy less than 12 months, as determined by the Investigator~* Subject is participating in another clinical study which has the potential to impact their hypertension management (pharmaceutical/device/homeopathic)~* Subject is pregnant, nursing, or of childbearing potential and is not using adequate contraceptive methods~* Subject has active systemic infection~* Subject has renal arteries with diameter(s) \< 4 mm in diameter~* Subject has an estimated GFR \<15 mL/min per 1.73 m\^2 using the MDRD formula~* Subject had a renal transplant or is awaiting a renal transplant~* Subject has blood clotting abnormalities

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A - EnligHTN for Severe Resistant HTN (Type: None): * Office systolic Blood Pressure ≥160 mmHg~* Subject is taking ≥3 anti-hypertensive medications (including 1 diuretic), or subject has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.~* Patient has an estimated GFR ≥45 mL/min per 1.73 m\^2 using the Modification of Diet in Renal Disease (MDRD) formula
- B - EnligHTN for Resistant HTN (Type: None): * Office systolic Blood Pressure ≥140 mmHg~* Subject is taking ≥3 anti-hypertensive medications (including 1 diuretic), or subject has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.~* Patient has an estimated GFR ≥45 mL/min per 1.73 m\^2 using the Modification of Diet in Renal Disease (MDRD) formula
- C - EnligHTN for Resistant HTN & CKD (Type: None): * Office systolic Blood Pressure ≥140 mmHg~* Subject is taking ≥3 anti-hypertensive medications (including 1 diuretic), or subject has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.~* Patient has an estimated ≥15 GFR \<45 mL/min per 1.73 m\^2 using the Modification of Diet in Renal Disease (MDRD) formula

Based on this trial design, predict the completion outcome and termination type (if applicable).